Logo image of XRTX

XORTX THERAPEUTICS INC (XRTX) Stock Fundamental Analysis

NASDAQ:XRTX - Nasdaq - CA98420Q3061 - Common Stock - Currency: USD

0.88  0 (0%)

Fundamental Rating

2

Taking everything into account, XRTX scores 2 out of 10 in our fundamental rating. XRTX was compared to 195 industry peers in the Pharmaceuticals industry. While XRTX seems to be doing ok healthwise, there are quite some concerns on its profitability. XRTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

XRTX had negative earnings in the past year.
XRTX had a negative operating cash flow in the past year.
In the past 5 years XRTX always reported negative net income.
XRTX had a negative operating cash flow in each of the past 5 years.
XRTX Yearly Net Income VS EBIT VS OCF VS FCFXRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

XRTX has a Return On Assets (-28.38%) which is comparable to the rest of the industry.
XRTX has a Return On Equity (-36.23%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -28.38%
ROE -36.23%
ROIC N/A
ROA(3y)-60.92%
ROA(5y)-49.27%
ROE(3y)-85.37%
ROE(5y)-73.65%
ROIC(3y)N/A
ROIC(5y)N/A
XRTX Yearly ROA, ROE, ROICXRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

XRTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XRTX Yearly Profit, Operating, Gross MarginsXRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, XRTX has more shares outstanding
The number of shares outstanding for XRTX has been reduced compared to 5 years ago.
Compared to 1 year ago, XRTX has a worse debt to assets ratio.
XRTX Yearly Shares OutstandingXRTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
XRTX Yearly Total Debt VS Total AssetsXRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

XRTX has an Altman-Z score of -7.12. This is a bad value and indicates that XRTX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -7.12, XRTX is not doing good in the industry: 65.64% of the companies in the same industry are doing better.
There is no outstanding debt for XRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.12
ROIC/WACCN/A
WACCN/A
XRTX Yearly LT Debt VS Equity VS FCFXRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

XRTX has a Current Ratio of 2.78. This indicates that XRTX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of XRTX (2.78) is comparable to the rest of the industry.
XRTX has a Quick Ratio of 2.78. This indicates that XRTX is financially healthy and has no problem in meeting its short term obligations.
XRTX's Quick ratio of 2.78 is in line compared to the rest of the industry. XRTX outperforms 52.82% of its industry peers.
Industry RankSector Rank
Current Ratio 2.78
Quick Ratio 2.78
XRTX Yearly Current Assets VS Current LiabilitesXRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

0

3. Growth

3.1 Past

XRTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.15%, which is quite impressive.
EPS 1Y (TTM)79.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.64%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XRTX Yearly EPS VS EstimatesXRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XRTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XRTX Price Earnings VS Forward Price EarningsXRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XRTX Per share dataXRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

XRTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XORTX THERAPEUTICS INC

NASDAQ:XRTX (6/13/2025, 4:00:38 PM)

0.88

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14
Earnings (Next)08-12 2025-08-12
Inst Owners7.58%
Inst Owner Change-99.84%
Ins Owners2.86%
Ins Owner ChangeN/A
Market Cap3.34M
Analysts80
Price TargetN/A
Short Float %0.23%
Short Ratio0.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.22
P/tB 1.3
EV/EBITDA N/A
EPS(TTM)-0.29
EYN/A
EPS(NY)-1.55
Fwd EYN/A
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0
BVpS0.72
TBVpS0.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.38%
ROE -36.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-60.92%
ROA(5y)-49.27%
ROE(3y)-85.37%
ROE(5y)-73.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.7%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.78
Quick Ratio 2.78
Altman-Z -7.12
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)48.3%
Cap/Depr(5y)87.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.95%
EPS Next Y-11.64%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y62.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y62.97%
OCF growth 3YN/A
OCF growth 5YN/A